摘要
目的探讨中期因子（midkine，MK）在子宫颈癌中的表达与临床病理特征的关系。方法采用免疫组织化学法（SP法）检测178例子宫颈癌组织中MK因子的表达情况。结果在178例宫颈癌组织中，MK蛋白阳性表达率为91．57％，临床Ⅱ～Ⅳ期阳性表达率明显高于临床Ⅰ期（P〈0．001）。子宫颈鳞癌MK阳性表达率显著高于腺癌（P〈0．001），但与组织分化程度无关（P=0．23）。有腹腔淋巴结转移者MK阳性表达率显著高于没有腹腔淋巴结转移者（P=0．026）。结论MK因子阳性表达与子宫颈癌病理特征关系密切，可能成为一种有价值的肿瘤标志物，对宫颈癌的早期诊断及治疗有一定的临床指导意义。
Objective To investigate the relationship between the expression of midkine factor（MK） and the clinical pathology in cervical cancer. Methods The expression of MK was detected by immunohistochemical technique in 178 cervical cancer specimens. Results Of the 178 cases,the positive expression rate of MK was 91.57 %. The significant difference was observed between the expressions of MK in specimens of clinical stage Ⅱ～Ⅳand stage Ⅰ（P 〈0. 001 ）. The positive expression rate of squamous carcinoma was higher than that of adenocarcinoma in the cervix （P 〈 0. 001 ） , but the significant difference was not found among the expressions of MK in specimens of different histodifferentiation （P = O. 123 ）. The positive expression rate was significantly higher in the patients with metastasis to celiac lymph nodes than that without metastasis （ P = 0.026）. Conclusion There is a close relation between the expression of MK and the clinical pathology in cervical cancer and it may be used as a tumor markers.
出处
《哈尔滨医科大学学报》
CAS
北大核心
2008年第6期622-624,共3页
Journal of Harbin Medical University
基金
黑龙江省自然科学基金资助项目(D2005-48)
